AbClon Inc. (KOSDAQ:174900)

South Korea flag South Korea · Delayed Price · Currency is KRW
52,000
-3,400 (-6.14%)
Apr 28, 2026, 3:30 PM KST
436.08%
Market Cap 1.04T
Revenue (ttm) 4.71B
Net Income (ttm) -17.91B
Shares Out 19.93M
EPS (ttm) -976.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 323,852
Average Volume 394,603
Open 55,200
Previous Close 55,400
Day's Range 51,600 - 55,200
52-Week Range 8,950 - 95,800
Beta 1.14
RSI 44.49
Earnings Date n/a

About AbClon

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company’s products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea. [Read more]

Sector Industrials
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 174900
Full Company Profile

Financial Performance

In 2025, AbClon's revenue was 4.71 billion, an increase of 101.47% compared to the previous year's 2.34 billion. Losses were -17.91 billion, 9.85% more than in 2024.

Financial Statements

News

There is no news available yet.